Indian clinical trial site closed over fraud
Glenmark Pharmaceuticals and Omnicare have closed a clinical trial site in India operated by the contract research organisation (CRO) amid accusations that an investigator acted fraudulently.
The site in Jamnagar, Gujarat, India employed A Bhattacharya, who has now been accused of fraudulent activities and suspended.
When Omnicare suspected fraudulent activity it and Glenmark performed the appropriate audit and contacted the authorities, according to a press statement.
An investigation will look at the allegations of fraud and Bhattacharya’s work with other pharma companies and CROs.
Following the news Glenmark released a statement that it will not consider data from the site. Glenmark has said that no patients have been put at risk.
